【摘要】 目的：为验证益肾填精方药“肾虚骨痛胶囊”防治骨质疏松症的疗效和探讨其治疗机理。方法：本文以切除卵巢雌性大鼠复制绝经后骨质疏松症模型，观察该药对去卵巢大鼠抗失骨作用。实验分为模型组、肾虚骨痛胶囊大、小剂量组、骨疏康阳性对照组和正常对照组。术后１周开始给药，持续１２０天。结果：肾虚骨痛胶囊大剂量组，与模型组比较，可以提高模鼠全身及股骨骨密度、股骨灰重、腰椎骨小梁体积、股骨无机元素 Ｃａ、 Ｐ、 Ｍｇ、 Ｚｎ、 Ｃｕ、 Ｍｎ含量，血清Ｅ_２含量用药后有增高之趋势，但与模型组比较无统计学差异。结论：肾虚骨痛胶囊可通过体内多方位调节作用达到预防和抑制骨质疏松症的发生和发展，具有较好的应用前景。更多还原

【Abstract】 Aim To test and verify the therapeutic effect of kidney tonifying and essence replenishing drugs. Shen Xu Gu Tong capsule (SXGTC), on prevention and treatment of osteoporosis and explore its therapeutic mechanism. Methods Postmenopausal osteoporosis models of 48 female rats were modelled by ovariectomy and divided into 4 groups: model group, large-and small-dose groups of SXGTC, and Gu Shu Kang positive control group, and other 12 rats in intact control group. The administration of drugs were started one week after operation and continued for 120 days. Results Comparing with model group, SXGTC in large dose can increase the bone density of the whole body skeleton and femur, the ash weight of femur, the volume of trabeculae in lumbar vertebra, and the contents of inorganic elements, Ca, P, Mg, Zn, Cu and Mn in femur. The content of serum E2 is inclinded to increase in SXGTC, but no statistical difference as compared with that in model group. Conclusion SXGTC can prevent and inhibit the occurrence and development of osteoporosis through internal regulation in many ways. So there is a better prospect for clinical application.更多还原